Progenics Plans to Seek Approval for Prostate Cancer Imaging Tool Following Phase III Results

Shares of Progenics Pharmaceuticals are up more than 20% in premarket trading after the company announced positive top-line results from its Phase III prostate cancer imaging tool PyL. The late-stage data sets up plans to seek regulatory approval in 2020.